Liver disease study aims to unlock secrets of weight loss surgery

NCT ID NCT04141592

Recruiting now Knowledge-focused Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares people with non-alcoholic fatty liver disease (NAFLD) to healthy controls to understand how the immune system, metabolism, and gut bacteria differ. Researchers will also track what happens to liver health in NAFLD patients who undergo weight loss surgery. The goal is to learn why some patients improve after surgery and identify markers that could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bariatric surgery (weight loss surgery)
What this could lead to: If successful, this could reveal key biological pathways in NAFLD and show whether weight loss surgery can reverse liver damage.
What could go wrong: This is an observational study, not a treatment trial. Results may not lead to new therapies, and findings may not apply to all NAFLD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

Homerton University Hospital Foundation Trust
RECRUITING

London, Greater London, E9 6SR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.